Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Nutlin-3a|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Nutlin-3a||Nutlin|Nutlin-3||MDM2 Inhibitor 20||Nutlin-3a is an MDM2 inhibitor which activates p53 and results in cancer cells undergoing apoptosis and cellular senescence. Nutlin-3 is a candidate for neoadjuvant therapy in cancers with a functional p53 (PMID: 18451145, PMID: 32653500).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 mutant||triple-receptor negative breast cancer||predicted - sensitive||Carboplatin + Nutlin-3a||Preclinical - Cell culture||Actionable||In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).||26494859|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|